top of page
ラボ用ピペットとバイアル

Drug Discovery

Targeting Cancer with Hairpin Nucleic Acids.

​

Cancer remains one of the leading causes of death worldwide.
We are addressing this global challenge with a novel strategy:
two hairpin-structured nucleic acids engineered to target cancer at the molecular level.

Nucleic Acid Technology

miRNA-Triggered Cell Death

Triggered by disease-specific miRNAs (miRNAs),
two hairpin-structured nucleic acids initiate a hybridization chain reaction (HCR), forming diffuse Nucleic Acid Aggregate Complex (NAAC) within the cytoplasm.

​

These NAAC are recognized by intracellular sensors as aberrant nucleic acids, activating innate immune pathways and inducing programmed cell death.

図1EN_edited.jpg

Pipeline Overview

Cancer Therapeutics

Current stage: Preclinical 

​

Mechanism of Action:
Activated by specific miRNAs, our therapeutic candidate triggers innate immune pathways and promotes the generation of cytotoxic T lymphocytes (CTLs), enhancing targeted immune responses.

​

Development Goal:
In combination with immune checkpoint inhibitors (ICIs), this therapy aims to offer a new treatment option for patients unresponsive to conventional ICI-based therapies.

We also plan to develop therapeutics for other diseases.

ワクチン生産ライン

Technology Overview

Academic Publication

A research paper by our founder, Professor Akimitsu Okamoto, and his team has been published in the international journal Journal of the American Chemical Society.

​

More information

​

Development Status & Details

For details regarding our drug discovery and development programs, please contact us via the inquiry form.

 

© 2025-2026 TKG Therapeutics, Inc.

bottom of page